Use of Probiotics as Adjunctive Treatment for Chronic Rhinosinusitis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00396162
Recruitment Status : Completed
First Posted : November 6, 2006
Results First Posted : August 4, 2016
Last Update Posted : September 20, 2016
Institut Rosell
Information provided by (Responsible Party):
Jeffrey E. Terrell, M.D., University of Michigan

Brief Summary:

Chronic sinusitis is reported to be one of the most widespread disorders in the United States. It can be caused by a variety of reasons such as allergy, infection and/or defects in T-cells which help regulate immune function. Medication and other costs related to treatment of nasal and sinus infections are estimated to be more than $60 million annually putting a considerable strain on the economy of health care.

Probiotics are live microorganisms that are normally present in the gut of a healthy individual. They are also known as "friendly bacteria" and have been used to help maintain the normal functioning of the immune system. They are safe and are commercially available in the form of yoghurt, sachets, chewable tablets or flavored capsules. Since a number of nasal and sinus disorders are related to allergy and improper functioning of the immune system, we hypothesize that regular use of probiotics may help improve chronic nasal and sinus symptoms by boosting immune responses.

The project we propose is novel because it would be the first study evaluating the usefulness of probiotics for the larger population having chronic sinusitis rather than those having only allergic symptoms. We aim to assess whether regular use of probiotics will help improve symptoms of chronic sinusitis and will have a greater effect than placebo in this regard.

Condition or disease Intervention/treatment Phase
Chronic Rhinosinusitis Drug: probiotic containing L.rhamnosus R0011 strain Other: Placebo Phase 4

Detailed Description:

Probiotics are live microorganisms which when administered in adequate amounts confer a health benefit on the host. They are a part of the normal gastrointestinal flora and have safely been used to boost immune responses in patients with perennial and seasonal allergic rhinitis. Their exact mechanism of benefit is unknown but they primarily help to regulate T-cell function which is important in maintaining immune tolerance.

Chronic rhinosinusitis is widely prevalent and affects nearly 16 million people in the US alone each year. It puts a strain on the health resources of the nation in terms of costs related to medications and surgery. Chronic rhinosinusitis can be caused by a variety of reasons including allergy/hypersensitivity, infection, nasal anatomical variations and T-cell regulatory dysfunction. We hypothesize that regular use of probiotics in patients with chronic rhinosinusitis will result in substantial improvement in their symptoms by boosting their immunity and may also help decrease their medication usage.

Our study will be a double-blinded, randomized, control trial. We hope to recruit 100 patients from the University Otolaryngology and Allergy Clinics. Fifty patients will be randomized to the treatment (active) arm and 50 patients to the placebo arm. Subjects will be followed for 2 months during their period of participation in the study.

The main aim of our study is to determine whether regular use of probiotics in patients with chronic rhinosinusitis helps improve their quality of life. Our main outcome of interest is a change in the mean score of the Sino-Nasal Outcome Test (SNOT-20) form in the treatment group and a greater change in the mean score of the SNOT-20 in the treatment arm as compared to the placebo arm. If probiotics are found to be effective, they may be used as a cost-effective, adjunctive therapy for patients with chronic rhinosinusitis.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 77 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: Use of Probiotics as Adjunctive Treatment for Chronic Rhinosinusitis
Study Start Date : November 2006
Actual Primary Completion Date : January 2008
Actual Study Completion Date : February 2008

Arm Intervention/treatment
Placebo Comparator: Placebo pill
Placebo pills on same schedule as active intervention.
Other: Placebo
Placebo pill

Active Comparator: Probiotic
L. rhamnosus R0011 strain
Drug: probiotic containing L.rhamnosus R0011 strain
500 million active cells of L rhamnosus R0011 strain per tablet bid for 4 weeks
Other Name: L rhamnosus R0011

Primary Outcome Measures :
  1. Mean Reduction in SNOT-20 Scores [ Time Frame: 8 weeks ]
    Mean reduction (and Standard deviation) in SNOT-20 scores, from baseline to 8 week measurements. SinoNasal Outcome Test measures symptom severity. It is a summary score, ranging from 0 to 100 with 100 indicating worse symptoms. Since 100 represents more severe symptoms, the changes represented here are reductions in SNOT-scores, even though they are not expressed as negative numbers.

Secondary Outcome Measures :
  1. Side Effect Summary [ Time Frame: 8 weeks ]
    Totals of all side effects for placebo group and treatment group over the course of the eight week trial (including patients who dropped from the study after baseline measurement). Individual categories of side-effects are listed in Adverse events section.

  2. Mean Number of Days of Antibiotic Use During the Study Period (0-8 Weeks) [ Time Frame: At 8 weeks after baseline measures ]
    Mean number of days that antibiotics were used in the subgroup (placebo vs Probiotic arm)

  3. Mean Number of Days of Steroid Spray Use for Each Group [ Time Frame: 8 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   15 Years to 70 Years   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Age ≥15 and ≤70 years.
  2. The patient must be bothered by each of the two following symptoms(>50% of days in the last 3 months):

    A. More than 12 consecutive weeks of symptomatic nasal obstruction and, B. More than 12 weeks of symptomatic nasal discharge.

  3. An Otolaryngologist evaluation and diagnosis of chronic inflammatory rhinosinusitis (hyperplastic mucosa, polyps in absence of overt bacterial infection)
  4. Access to telephone (home or person cell).

Exclusion Criteria:

  1. Sinus surgery within the last 3 months
  2. Acute illness within the last 2 weeks requiring antibiotics: including: otitis media, pharyngitis, bronchitis, or laryngitis.
  3. Immunosuppression (due to medications including oral steroids, or due to autoimmune diseases, HIV infection, cystic fibrosis, immunodeficiency, malignancies, uncontrolled diabetes mellitus, chronic renal failure, etc.)
  4. Patients with chronic or acute bacterial sinusitis.(Clinical diagnosis-to be decided by MD)
  5. An allergic reaction to a probiotic dietary supplement in the past (such as symptoms of tightness in the chest, breathing difficulties, skin hives, rash or other clinical symptoms consistent with sensitivity or intolerance)
  6. Inability to speak or read English.
  7. Pregnancy and Lactation

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00396162

Sponsors and Collaborators
University of Michigan
Institut Rosell
Principal Investigator: Jeffrey E Terrell, MD University of Michigan

Responsible Party: Jeffrey E. Terrell, M.D., Professor of Otolaryngology, University of Michigan Identifier: NCT00396162     History of Changes
Other Study ID Numbers: HUM00006212
First Posted: November 6, 2006    Key Record Dates
Results First Posted: August 4, 2016
Last Update Posted: September 20, 2016
Last Verified: August 2016

Additional relevant MeSH terms:
Paranasal Sinus Diseases
Nose Diseases
Respiratory Tract Diseases
Respiratory Tract Infections
Otorhinolaryngologic Diseases